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Naloxone lowers cerebrospinal fluid levels of
excitatory amino acids after thoracoabdominal
aortic surgery
Takashi Kunihara, MD, PhD,a Kenji Matsuzaki, MD,a Norihiko Shiiya, MD, PhD,a
Yasuaki Saijo, MD, PhD,b and Keishu Yasuda, MD, PhD,a Sapporo, Japan
Objective: Although naloxone has been used to prevent ischemic spinal cord injury (SCI), its effect on excitatory amino
acids (EAAs) has not been understood. We investigated the clinical significance of naloxone by measuring EAAs in the
cerebrospinal fluid (CSF) in patients undergoing thoracoabdominal aortic surgery.
Methods and subjects: Twenty-seven patients (15 men and 12 women; mean age, 66  12 years) undergoing prosthetic
replacement of the thoracoabdominal aorta (n  19) or the descending thoracic aorta (n  8) from April 1997 to June
2003 under distal perfusion and mild hypothermia were enrolled in this cohort study with historical controls. Their
etiology was 7 dissections and 20 nondissections. In 16 patients (naloxone group), intravenous infusion of naloxone
(1 g/kg/h) was continued until the patients became alert. In the remaining 11 patients (control group) naloxone was
not given. CSF drainage was used in all patients. CSF levels of EAAs, glutamate, aspartate, and glycine were measured at
6 points in time until 72 hours postoperatively, using a high-performance liquid chromatography method.
Results: In 5 patients with SCI (2 patients in control group, 3 in naloxone group), CSF levels of glutamate and glycine
continued to increase even at 72 hours postoperatively, and were significantly more elevated than those in patients
without SCI (P < .0001, glutamate; P  .0006, glycine). Postoperative maximum levels of CSF glutamate and glycine
were also significantly higher in patients with postoperative SCI than in patients without SCI (glutamate: 215.3% 
158.6% vs 32.9% 37.3% increase from baseline, P < .0001; glycine: 309.1% 218.2% vs 89.2% 103.1% increase from
baseline, P  .0036). CSF levels of glutamate and aspartate in naloxone group were significantly lower than those in
control group (P  .0161, glutamate; P < .0001, aspartate). Postoperative maximum level of CSF aspartate was also
significantly lower in the naloxone group than in the control group (8.3%  75.5% vs 119.7%  120.6% increase from
baseline, P  .0077). In multivariate logistic regression analysis, postoperative maximum CSF glutamate >100% from
baseline (P < .001) and postoperative maximum level of CSF glycine (P  .005) were identified as the independent risk
factors for SCI. Both SCI (P < .001) and postoperative maximum level of CSF glycine (P  .005) were the independent
predictors for postoperative maximum level of CSF glutamate >100% from baseline.
Conclusions: CSF levels of EAAs are elevated in patients with SCI. CSF glutamate is the strongest independent predictor
of SCI. Naloxone is effective in lowering CSF levels of EAAs. (J Vasc Surg 2004;40:681-90.)Although a large number of experimental works and
technical advances have concentrated on improving out-
come in thoracoabdominal aortic surgery, spinal cord in-
jury (SCI) still remains the most formidable morbidity to be
resolved. Cerebrospinal fluid (CSF) drainage may be one of
the most promising procedures to prevent SCI. Acher and
associates1 have reported that combined use of CSF drain-
age (CSFD) and naloxone hydrochloride (naloxone), an
opioid receptor antagonist, reduces the risk of SCI in
patients undergoing thoracoabdominal aortic surgery. Re-
cently, CSFD itself proved to be beneficial in reducing the
risk of SCI after thoracoabdominal aortic surgery in a
prospective randomized clinical trial.2 However, it has not
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The mechanisms underlying neurologic injury subse-
quent to ischemia appear to be multifactorial. The discov-
ery of increased cerebral extracellular concentrations of
glutamate and aspartate related to ischemia has triggered
enormous interest in this phenomenon.3 Generally, exces-
sive synaptic accumulation of glutamate during ischemia is
associated with neuronal cell damage, which is mediated
through overactivation of glutamate receptor followed by
excessive influx of calcium. This is the current excitotoxic
concept of ischemia-induced neuronal cell death.4 Neuro-
transmitter amino acids including glutamate, aspartate, gly-
cine, gamma-aminobutyric acid, and taurine are known as
excitatory amino acids (EAAs). Much evidence has sug-
gested that the most changes in EAAs occur selectively in
the extracellular space where neuroactive drugs are avail-
able.4 Therefore, EAA-mediated excitotoxicity provides
important therapeutic implications for neuroprotective ap-
proach in patients suffering from ischemia. Recently, EAA
activities in the CSF have been investigated in patients with
ischemic insult because it is easier and simpler to obtain
CSF than extracellular fluid (ECF) in clinical cases.5-7 Ele-681
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associated with ischemic neurologic insults.5-7 In the field
of thoracoabdominal aortic surgery, it has also been re-
ported that patients with postoperative SCI manifested
elevated levels of EAAs in the CSF.8 Therefore, it is reason-
able to speculate that in Acher et al’s study,1 both CSFD
and naloxone contributed to a reduction in the risk of SCI
by attenuating EAAs in the CSF in addition to reducing
CSF pressure.
Although it has been shown that high concentration of
naloxone attenuates N-methyl-D-aspartate (NMDA)–
mediated neurotoxicity in an animal model,9 there has been
no report to demonstrate that naloxone reduces CSF EAA
levels in patients suffering spinal cord ischemia or reperfu-
sion caused by temporal aortic cross-clamping (AXC). Fur-
thermore, little is known about the alterations of CSF EAA
levels up to 72 hours after operation, which may interest
investigators since neurotoxicity mediated by EAAs is sup-
posed to be a late-onset process.10-12
The purpose of this study is to elucidate the alterations
of EAA levels in the CSF up to 72 postoperative hours and
to test the hypothesis that naloxone given intravenously
attenuates EAA levels in the CSF in patients undergoing
descending thoracic or thoracoabdominal aortic surgery.
PATIENTS AND METHODS
Twenty-seven patients who underwent prosthetic re-
placement of the descending thoracic or the thoracoab-
dominal aorta and CSFD at Hokkaido University Hospital
between April 1997 and June 2003 were enrolled in this
study. CSFD was approved by the medical ethics commit-
tee of Hokkaido University, and a written informed con-
sent was given by all patients. There were 15 male and 12
female subjects, and their ages ranged from 26 to 79 (mean,
66  12). The etiology of disease was dissection for 7
(including 3 Marfan syndrome) and nondissection degen-
erative disease for 20 patients. Twenty-five patients under-
Table I. Patient characteristics
Characteristics Naloxon
Age (y) 69.9
Gender (male) 10
Etiology (dissection) 4
Emergent/urgent operation 0
Previous aortic surgery 4
Extent (thoracoabdominal aorta) 10
Crawford classification (I/II/III) 5/
Involved intercostal/lumbar arteries 6.8
Reattached intercostal/lumbar arteries 2.6
Total amount of CSFD (mL) 269
Daily amount of CSFD (mL/d) 88
Duration of operation (min) 447
Duration of CPB (min) 119
Duration of AXC (min) 119
The lowest rectal temperature (°C) 33.7
Hospital death 1 (
Spinal cord injury 3went elective operation, while 2 patients underwent non-
elective operation for contained or impending rupture (the
former developed paraplegia). Eight patients had aortic
diseases in the descending thoracic aorta and 19 patients in
the thoracoabdominal aorta (Crawford type I for 7 pa-
tients, type II for 4, and type III for 8). Seven patients had
undergone previous aortic surgery—from the aortic root to
the aortic arch in 2 patients, the distal aortic arch in 2, the
abdominal aorta in 2, and the abdominal aorta followed by
the aortic arch in 1. As a method to protect the spinal cord,
continuous intravenous infusion of naloxone at a rate of
1g/kg/h was used in the last 16 patients after April 2000.
For the analysis of EAAs, the patients were divided into 2
groups according to naloxone administration: (1) the con-
trol group consisted of the patients who received no nalox-
one treatment (n  11), and (2) the naloxone group
consisted of patients who were given naloxone as described
previously (n  16). Characteristics of the patients in each
group are demonstrated in Table I. In the naloxone group,
mean age was older than in the control group, but there was
no significant difference between the 2 groups in patient
characteristics except the use of naloxone.
Technique of operation. Except for the use of nalox-
one, all patients received the same protocol of anesthesia
with neuromuscular blockade and intermittent intravenous
injection of fentanyl citrate. Separate bronchial ventilation
was employed and the left lung was collapsed during the
operative procedure. Operations were performed through a
left posterolateral thoracotomy, with or without a thoraco-
abdominal incision. All patients underwent prosthetic re-
placement of the diseased aorta; 7.3 3.6 (range, 2 to 15)
pairs of the intercostal or lumbar arteries were involved in
the diseased aortic segments, and 2.9 1.5 (range, 0 to 6)
pairs of them were reattached by using evoked spinal cord
potential guidance. Partial femorofemoral (F-F) cardiopul-
monary bypass (CPB) with mild hypothermia (lowest rectal
temperature, 33.9  1.0°C) was employed in all patients.
Group
P16) Control (n  11)
60.8 16.4 .0556
) 5 (45%) .3811
) 3 (27%) .8947
2 (18%) .0763
) 3 (27%) .8947
) 9 (82%) .2801
2/3/4 .3264
8.0 3.8 .4051
3.4 1.6 .1857
1 201 200 .4756
64 60 .3214
8 554 238 .2559
133 75 .5805
113 64 .8313
34.1 1.0 .3700
0 .3981
) 2 (18%) .9702e (n 
 6.7
(62%
(25%
(25%
(63%
1/4
 3.4
 1.5
 25
 57
 22
 56
 56
 1.0
6%)
(18%
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creases the release of EAAs, patients subjected to deep
hypothermic operation were excluded.13,14 Initial flow of
F-F bypass was set at 1.8 L/min/body surface area (m2),
and sequential clamp technique was applied as far as possi-
ble. When reconstruction of visceral branches was required,
each branch was cannulated with a balloon catheter and
perfused at a rate of 150mL/min until it was reattached to
the graft.
The equipment of CPB was completely heparin-coated
(Hepaface; Terumo, Tokyo, Japan) and consisted of a centrif-
ugal pump (Medtronic Bio-Medicus Inc, Eden Prairie, Minn)
and a membrane oxygenator (Capiox SX-18; Terumo). This
system was primed with lactated Ringer’s solution and 5
mg/kg of betamethasone. The same dose of betamethasone
was also given intravenously before initiation of CPB. In
patients undergoing F-F bypass with cardiotomy sucker (n
22), 2mg/kg of heparin was used, while 1mg/kg of heparin
was given to patients undergoing F-F bypass that was con-
structed by a closed system without a cardiotomy reservoir (n
 5). A centrifugal cell-saving device (Cell Saver 5; Haemon-
etics, Braintree, Mass) was used in all patients during the
operation. Postoperatively shed mediastinal blood was dis-
carded.
Cerebrospinal fluid drainage and measurement of
EAAs. Lumbar CSFD was performed through a 16-gauge
in-dwelling catheter, which was inserted into the L4/5
intervertebral space after induction of the anesthesia. CSF
was allowed to freely drain if CSF pressure exceeded 13-cm
H2O. CSFD was started just after the induction of anesthe-
sia and was continued until 72 hours after surgery unless no
CSF was drained. Samples of CSF were collected just before
operation and 0, 12, 24, 48, and 72 hours after operation.
The CSF samples were centrifuged and the supernatant was
immediately frozen at –80°C for the later measurements.
CSF levels of 3 EAAs—glutamate, aspartate, and glycine—
were measured by high-performance liquid chromatogra-
phy (JLC-500V; Nihon Denshi, Ltd, Tokyo, Japan).
Statistical analysis. All values are expressed as mean
standard deviation. Statistical analysis was performed with
the StatView 5.0 program (SAS Institute Inc, Cary, NC)
except for logistic regression analysis, which was performed
with SPSS (SPSS, Inc, Chicago, Ill). Repeated-measures
analysis of variance was used for comparisons of EAA levels
between the groups. The Student t test was used for com-
parison of the continuous variables and the 2 test was used
for comparison of frequencies between the groups. A P
value .05 was considered statistically significant.
RESULTS
There was 1 hospital death in the control group due to
small intestinal necrosis caused by dissection of the superior
mesenteric artery 166 days after the operation for nondis-
secting thoracoabdominal aortic aneurysm. This event had
no effect on the results of this study, since the early post-
operative course of this patient was uneventful and dissec-
tion occurred 37 days after the operation.Postoperative SCI occurred in 5 patients (1 with para-
plegia and 2 with paraparesis in the naloxone group, 1 with
paraplegia and 1 with paraparesis in the control group).
One of the paraplegic patients in the control group also had
multiple cerebral infarctions in the left hemisphere that
resulted in right hemiparesis. This patient underwent an
emergent operation for contained rupture of the descend-
ing thoracic aortic aneurysm. Spinal cord functions of the 2
patients with paraparesis in the control group recovered
almost completely within 2 months. Of these patients, 2
had nondissection degenerative aneurysms on the descend-
ing thoracic aorta and 2 on the thoracoabdominal aorta
(type I and III); the remaining patient with chronic dissec-
tion underwent replacement of the descending thoracic
aorta. Neither hospital mortality nor incidence of postop-
erative SCI was significantly different between the 2
groups. No other neurologic morbidity was experienced.
There were no complications related to CSFD. Mean
duration of postoperative CSFD and total volume of CSFD
in all patients were 2.8  1.1 days and 238  227 mL (77
 58 mL/d). Both the total and daily volume of CSFD was
similar between the 2 groups (Table I). Mean duration of
operation, CPB, and AXC in all patients were 492  234,
125  64, and 117  58 min, respectively. There was also
no significant difference in these intraoperative data be-
tween the 2 groups (Table I).
In 5 patients with postoperative SCI, glutamate and
glycine levels in the CSF kept increasing even at 72 hours
after the operation and were significantly higher than those
in patients without SCI (P .0001, glutamate; P .0006,
glycine; Figs 1 and 2). CSF aspartate in patients with
postoperative SCI peaked at 12 hours postoperatively and
decreased gradually up to 72 hours after the operation. The
level seemed higher than those in patients without SCI,
although this difference was not significant (P .3894; Fig
3). Postoperative maximum levels of CSF glutamate and
glycine were also significantly higher in patients who suf-
fered from postoperative SCI than in those without SCI
(glutamate, 215.3% 158.6% vs 32.9%  37.3% increase
from baseline, P  .0001; glycine, 309.1%  218.2% vs
89.2% 103.1% increase from baseline, P .0036; Fig 4).
Postoperative maximum level of CSF aspartate was also
higher in patients with postoperative SCI than the rest
(84.8%  97.4% vs 43.1%  111.3% increase from base-
line), although it did not have statistical power (Fig 4).
In patients with naloxone treatment, CSF glutamate
and aspartate peaked at 48 and 24 hours after the opera-
tion, respectively, followed by a gradual decrease. CSF
aspartate returned to baseline level at 72 hours after sur-
gery. These 2 EAA levels in the CSF were significantly
higher in the control group than in the naloxone group
(P .0161 for glutamate and P .0001 for aspartate; Figs
5 and 6). CSF glycine level in both groups kept increasing
even at 72 hours after the operation, although there was no
significant difference between the groups (P  .3629,
Fig 7). Postoperative maximum level of CSF aspartate was
also significantly lower in patients who underwent nalox-
one treatment than in those given no naloxone (8.3% 
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.0077; Fig. 8). The same trend was found in glutamate and
glycine, but they did not reach statistical difference (gluta-
mate, 50.1%  43.8% vs 80.1%  142.5% increase from
baseline, P  .4495; glycine, 119.4%  118.0% vs 131.9%
 189.1% increase from baseline, P .8398; Fig 8). Table
II includes original data for CSF EAAs in patients with or
without postoperative SCI or naloxone treatment.
To clarify the independent risk factors for SCI or ele-
vation of CSF EAAs, logistic regression analysis was per-
formed. A P value .20 in univariate analysis was defined
for selecting variables for entry into the multivariate model.
(See Appendix, online only, for variables used in analysis).
In multivariate analysis, postoperative maximum levels of
CSF glutamate 100% from baseline (more than twice as
large as preoperative values) and postoperative maximum
level of CSF glycine were identified as the significant inde-
pendent risk factors for SCI (Table III). When postopera-
tive maximum levels of CSF EAAs 100% from baseline
Fig 1. Time course of glutamate levels in the cerebrospi
cord injury. All figure error bars represent standard devia
Fig 2. Time course of aspartate levels in the cerebrospin
cord injury.were defined as the outcome event, no significant indepen-
dent risk factors were found for aspartate and glycine.
However, both SCI and postoperative maximum level of
CSF glycine were significant predictors for glutamate. Es-
pecially since postoperative maximum levels of CSF gluta-
mate for all patients with SCI were larger than 100%
from baseline, SCI and maximum levels of CSF gluta-
mate100% proved to be the strongest predictor of each
other.
DISCUSSION
In the current study, we confirmed that elevated levels
of EAAs in the CSF were associated with postoperative SCI
for at least 72 postoperative hours. This result not only
confirmed a previous report by Brock and colleagues8 but
also disclosed alterations of CSF EAA levels until 72 hours
after thoracoabdominal aortic surgery. Furthermore, we
were able to clearly demonstrate that naloxone dramatically
reduced CSF EAA levels in patients who underwent spinal
id (CSF) in patients with or without postoperative spinal
All data are presented by percent change from baseline.
id (CSF) in patients with or without postoperative spinalnal flu
tion.al flu
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the first report to demonstrate that intravenous naloxone
reduces CSF EAA levels in patients undergoing thoracoab-
dominal aortic surgery.
The alteration of EAAs in the CSF of patients with
brain injury such as ischemic stroke,5 traumatic injury,6 and
subarachnoid hemorrhage,7 or degenerative diseases such
as amyotrophic lateral sclerosis15 and Alzheimer’s disease16
are well documented. However, little is known about the
production of EAAs in the CSF during the process of spinal
cord ischemia/reperfusion due to thoracoabdominal aortic
surgery.8 Sustained release of glutamate has been observed
for several days following traumatic brain injury17 or mas-
sive cerebral infarction.18 In our findings, glutamate and
glycine levels in the CSF in patients with postoperative SCI
kept on increasing even at 72 hours after operation. Re-
Fig 3. Time course of glycine levels in the cerebrospina
cord injury.
Fig 4. Postoperative maximum levels of CSF EAAs fo
presented by percent change from baseline.cently, excitotoxicity has been presumed to be a delayed
process.10,11 It has been reported that glutamate receptor
antagonist administered after the ischemic insult could
provide neuronal protection.10,12 Our results suggest that
patients subjected to thoracoabdominal surgery are always
faced with the risk of delayed onset SCI mediated by
excitotoxicity.
After first report by Benveniste and colleagues3 in 1984
of increased extracellular concentrations of glutamate and
aspartate during ischemia, much evidence has supported
the idea that several mechanisms and multiple subcellular
origins are involved in this phenomenon.4 Ischemia-
induced increase in ECF glutamate can mainly originate
from Ca2-dependent release19 (ie, neuronal origin) and
Ca2-independent release20 (ie, metabolic origin). Recent
studies have supported the fact that both magnitude and
(CSF) in patients with or without postoperative spinal
ients with and without spinal cord injury. All data arel fluidr pat
brosp
rosp
JOURNAL OF VASCULAR SURGERY
October 2004686 Kunihara et alduration of Ca2-dependent glutamate increase related to
ischemia and hypoxia seem minor compared with the total
elevation of ECF glutamate. It has been well established
that accumulated ECF glutamate during ischemia is rapidly
cleared during reperfusion.3,4 Therefore, we speculated
that sustained release of EAAs observed in our patients
either was mainly of metabolic origin or was caused by
sustained ischemia or both. The fact that glutamate recep-
tor antagonist given after the ischemic insult could attenu-
ate neuronal injury10,12 supports this speculation.
Since Baskin’s group reported reversal of ischemic neu-
rologic deficits using naloxone both in animals21 and hu-
mans22 in the early 1980s, multifactorial mechanisms un-
derlying this beneficial effect of naloxone have been
discussed. Several studies have demonstrated that naloxone
enhances blood pressure and spinal cord blood flow.23,24
In patients undergoing thoracoabdominal aortic surgery,
Fig 5. Time course of glutamate levels in the cere
Fig 6. Time course of aspartate levels in the cerebsystemic blood pressure seems to be maintained steadily.
Therefore, this beneficial effect of naloxone may be inferred
by improved spinal cord microcirculation rather than by
increased blood pressure solely. It is not known whether
EAA leak is a direct or indirect effect or cause of SCI.
Possible indirect effects of naloxone include the reduction
of the degree of ischemic insult and avoidance of sustained
ischemia after reperfusion by enhancing spinal cord micro-
circulation, thereby limiting the leak of EAAs into the CSF.
Improved spinal cord microcirculation may also help atten-
uate EAA release of metabolic origin. The previous findings
that ECF glutamate in the cerebral cortex is dependent on
cerebral blood flow in a threshold manner may partially
support this hypothesis.25 Another possible mechanism of
naloxone in lowering EAAs is mediation by antioxidant
action26 that can control calcium flux27 and effect cyclic
adenosine monophosphate.28
inal fluid (CSF) in patients given naloxone or not.
inal fluid (CSF) in patients given naloxone or not.
rospin
line.
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the mammalian central nervous system. Excessive synaptic
accumulation of glutamate related to ischemia may injure
neuronal cells and is mediated through overactivation of
glutamate receptors and excessive influx of calcium. This
process of neuronal cell death is known as excitotoxicity.29
Glutamate receptor subtypes are divided into ionotoropic
and metabotropic, and the former is further classified into
NMDA and non-NMDA types. The mechanism by which
naloxone attenuates CSF levels of EAAs remains unclear
because naloxone has been believed to be a nonselective
opioid receptor antagonist. Kim et al9 have demonstrated
that high concentrations of naloxone could partially antag-
onize NMDA receptor-mediated neurotoxicity in an ani-
Fig 7. Time course of glycine levels in the cereb
Fig 8. Postoperative maximum levels of CSF ENAAs c
not. All data are presented by percent change from basemal model. However, it has been unknown whether a very
low dose of naloxone, which has been used during thora-
coabdominal aortic replacement,1 can ameliorate NMDA-
mediated excitotoxicity or not. A possible explanation is
that the sigma opioid receptor may be related to the
NMDA receptor channel, where naloxone has weak bind-
ing affinity.30,31 Further experimental studies will be re-
quired to clarify the mechanism underlying the effects of
naloxone on CSF glutamate.
There is increasing evidence that nonglutamatergic
neurotransmitters also play a key role in the pathogenesis of
excitotoxicity. Glycine is supposed to be both a coagonist
of glutamate on the NMDA receptor that can potentiate
the inflow of glutamate-dependent calcium into the cell
al fluid (CSF) in patients given naloxone or not.
red between patients underwent naloxone-treatment orompa
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separate receptor in the spinal cord.8,32,33 Glycine has the
highest concentration among all amino acids in the ventral
gray matter that is the most vulnerable area to hypoxia/
ischemia in the spinal cord.34 In a swine model of ischemia
and reperfusion of the spinal cord, the alteration of ECF
glycine level paralleled that of glutamate, which was re-
versed by a noncompetitive NMDA receptor antagonist.32
The findings in the current study that postoperative maxi-
mum level of CSF glycine was a significant predictor for
postoperative maximum level of CSF glutamate 100%
from baseline are consistent with this observation. It has
also been demonstrated that glycine antagonists attenuate
neurotoxicity mediated by glutamate receptors.35 Clini-
cally, CSF glycine level has been reported to be the most
predictive independent factor of severity of stroke at 48
Table II. Time course of excitatory amino acid levels (nm
postoperative spinal cord injury or naxolone treatment.
Spinal cord i
(–)
Glutamate baseline 3.46 2.04
0 h 3.42 1.56
12 h 2.92 1.13
24 h 3.42 1.28
48 h 4.46 1.86
72 h 4.73 1.65
Aspartate baseline .29  .35
0 h .30  .31
12 h .37  .48
24 h .79  2.21
48 h .29  .32
72 h .09  .07
Glycine baseline 8.94 6.79
0 h 10.23  6.91
12 h 12.26  9.36
24 h 16.40  13.88
48 h 19.36  20.04
72 h 24.41  26.04
Table III. Logistic regression analysis to identify indepen
maximum levels of CSF EAAs 100% from baseline.
Outcome Variable
Spinal cord injury Extent (thoracoabdominal aorta)
Max. glutamate 100%
Max. glycine
Max aspartate 100% Naloxone
Duration of operation
CSFD amount/day
Max glutamate 100% Spinal cord injury
Max. glycine
Max glycine 100% Spinal cord injury
Max. glutamate
Duration of ventilation
CSF, Cerebrospinal fluid; EAA, excitatory amino acid; uni, univariate; multi
applicable.
*Since postoperative maximum levels of CSF glutamate of all patients with s
be calculated.hours after the onset.5 Our results that CSF glycine level in
patients with SCI showed the most pronounced elevation
among the 3 investigated EAAs are consistent with this
report.
Although the role of aspartate in excitotoxicity is not
well established, the high concentration of aspartate has
been revealed in animal models36 and in humans with
ischemic neurologic insults.7 Our patients with SCI also
suffered from a higher CSF aspartate level than those
without SCI, although it had no statistical power. These
findings are also in agreement with Brock et al’s study.8
Furthermore, CSF aspartate level peaked at 24 hours
after surgery in patients without naloxone treatment,
and both its time course and its maximum level were
significantly ameliorated by naloxone. These data are
consistent with transient increase of aspartate in animal
) in the cerebrospinal fluid in patients with and without
Naloxone treatment
() (–) ()
40 .99 3.54 2.29 3.12 1.73
33 1.67 3.56 1.70 3.31 1.49
92 2.88 3.90 1.81 2.69 1.34
60 2.19 3.85 1.67 3.24 1.25
25 7.93 8.35 7.01 3.91 2.18
40 6.55 8.25 5.81 4.24 1.87
55  1.50 .86 1.03 .25 .44
78  .78 .62  .27 .23  .45
70  1.16 1.01 .86 .23 .54
80 1.04 2.08  3.16 .09 .10
17  2.71 2.33 2.56 .21 .31
87  2.28 1.32 2.13 .15 .18
12  5.70 12.98 8.40 6.56 3.19
88 3.58 13.31  8.85 7.97 3.34
35 14.19 18.73 11.40 10.03 8.82
83 5.65 22.27 13.91 12.23 11.14
12 41.92 41.80 38.27 15.53 18.62
88 55.16 54.62 52.97 18.84 20.76
predictors for spinal cord injury or postoperative
Uni Multi OR 95% CI
.119 .285 NA
.001 .001 NA ()*
.042 .005 NA
.103 .370 2.496 .338–18.427
.148 .133 1.004 .999–1.009
.197 .137 .982 .959–1.006
.001 .001 NA ()*
.042 .005 NA
.150 .722 2.038 .040–103.119
.116 .176 1.022 .990–1.056
.180 .167 1.645 .812–3.333
ivariate; OR, odds ratio; CI, confidential interval; Max, maximum; NA, not
cord injury were larger than 100% from baseline, OR and 95% CI could notol/L
njury
2.
3.
4.
3.
7.
7.
1.
.
1.
.
2.
1.
10.
8.
23.
12.
34.
44.dent
, mult
pinal
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cord.14,32,36 Further research will be necessary to explain
these results.
The interpretation of our results must be carefully
evaluated. First, we performed CSFD continuously until 72
hours after operation. CSFD itself may reduce CSF EAA
levels, and may therefore have influenced the results. To
clarify the effects of CSFD itself on the alteration of EAAs in
the CSF, it is necessary to have a control group in which
samples of CSF were collected without continuous CSFD,
although it seems unethical. Second, this study is not a
randomized study and has a patient selection bias. For
example, 2 patients who underwent nonelective operation
for contained or impending rupture were included in the
current study. However, logistic regression analysis re-
vealed that nonelective operation did not affect incidence
of SCI nor CSF levels of EAAs at all. Third, we could not
find the risk of postoperative SCI reduced by naloxone itself
in our small cohort. Replication in larger prospective ran-
domized clinical trials is needed. In addition, the mecha-
nism of SCI after thoracoabdominal aortic surgery is mul-
tifactorial. Although there was no significant difference in
involved or reattached intercostals and lumbar arteries or
intraoperative variables between groups, the operative
technique (ie, duration of spinal cord ischemia) or result of
reconstruction (ie, failure or patency of reattached intercos-
tals and lumbar arteries that are critical to the spinal cord) is
not uniform between the groups. Furthermore, even post-
operative factors that are not directly related to the opera-
tive technique, such as perioperative hypotension (post-
ischemic poor perfusion) or thrombosis and embolism of
critical intercostals and lumbar arteries, can be associated
with SCI. Therefore, our results warrant further investiga-
tion in animal models under uniform conditions.
In conclusion, patients with postoperative SCI are ex-
posed to high concentrations of EAAs in the CSF for at
least 72 hours after thoracoabdominal aortic surgery. These
results may provide partial support for the rationale that
excitotoxicity mediated by EAAs is responsible for isch-
emia/reperfusion injury of the spinal cord that is related to
AXC. Sustained elevation of EAAs was reduced by intrave-
nous naloxone, suggesting important therapeutic implica-
tions of this compound for patients undergoing thoracoab-
dominal aortic surgery.
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